<div id="readability-page-1"><p>Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the twelve analysts that are currently  covering the company, MarketBeat Ratings reports. One research analyst  has rated the stock with a sell recommendation, one  has assigned  a hold recommendation and ten have issued  a buy recommendation on  the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $22.8182.</p><p>A number of analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Alphatec in a research report on Tuesday, October 28th. They set a &#34;buy&#34; rating and a $20.00 price target on the stock. JPMorgan Chase &amp; Co. started coverage on Alphatec in a research note on Friday, October 24th. They set an &#34;overweight&#34; rating and a $19.00 price objective for the company. Canaccord Genuity Group raised their target price on Alphatec from $20.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Alphatec from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday. Finally, Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Alphatec in a report on Monday, December 29th.</p><p><b>Get Our Latest Research Report on Alphatec</b></p><h2>Insider Buying and Selling</h2><p>In other news, Director David R. Pelizzon sold 250,000 shares of Alphatec stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $19.66, for a total transaction of $4,915,000.00. Following the sale, the director owned 10,395,045 shares of the company's stock, valued at approximately $204,366,584.70. The trade was a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Craig E. Hunsaker sold 32,584 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $20.84, for a total value of $679,050.56. Following the completion of the transaction, the executive vice president directly owned 1,256,558 shares of the company's stock, valued at $26,186,668.72. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 2,933,342 shares of company stock valued at $60,928,781 in the last ninety days. Insiders own  22.80% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the business. Emerald Advisers LLC grew its holdings in  Alphatec by 3.8% during the second quarter. Emerald Advisers LLC now owns 1,684,334 shares of the medical technology company's stock worth $18,696,000 after acquiring an additional 60,885 shares during the period.  Assenagon Asset Management S.A. lifted its holdings in  Alphatec by 7,083.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 750,429 shares of the medical technology company's stock valued at $10,911,000 after acquiring an additional 739,982 shares during the last quarter.  American Century Companies Inc. boosted its position in shares of  Alphatec by 6.0% during the 2nd quarter. American Century Companies Inc. now owns 6,177,161 shares of the medical technology company's stock valued at $68,567,000 after purchasing an additional 347,130 shares in the last quarter.  Truist Financial Corp bought a new position in shares of  Alphatec during the 2nd quarter valued at about $216,000.  Finally, Lisanti Capital Growth LLC acquired a new position in shares of  Alphatec in the 3rd quarter worth approximately $3,305,000. 66.35% of the stock is owned by institutional investors and hedge funds. </p><h2>Alphatec Trading Down 0.1%</h2><p>Alphatec stock opened at $14.83 on Monday. Alphatec has a 1 year low of $8.81 and a 1 year high of $23.29. The firm's 50-day moving average is $19.65 and its 200-day moving average is $16.97. The company has a debt-to-equity ratio of 43.02, a quick ratio of 1.24 and a current ratio of 1.99. The company has a market cap of $2.20 billion, a P/E ratio of -14.26 and a beta of 1.01. </p><p>Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.09. The business had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period in the prior year, the company earned ($0.28) EPS. Alphatec's quarterly revenue was up 30.4% on a year-over-year basis.  On average, equities analysts expect that  Alphatec will post -1.08 earnings per share for the current year. </p><h2>About Alphatec</h2> (Get Free Report)<p>Alphatec Holdings, Inc <span>NASDAQ: ATEC<span></span></span> is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company's portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec's flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.  </p><p>Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Alphatec</li><li>Trump just signed it</li><li>A Message From An Ex-CIA Officer About Trump</li><li>Buy this Gold Stock Before May 2026</li><li>New Banking Law #1582 Could Unlock $21 Trillion for Americans</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVRFQw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Alphatec Right Now?</h2><p>Before you consider Alphatec, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alphatec wasn't on the list.</p><p>While Alphatec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

ATEC

<p>Alphatec Holdings, Inc. (NASDAQ:ATEC) has received a consensus rating of "Moderate Buy" from twelve analysts. The average 12-month target price is $22.82, with ten analysts recommending a buy, one a hold, and one a sell. Recent coverage includes a buy rating from Stifel Nicolaus with a $20 target and an overweight rating from JPMorgan with a $19 target. Insider trading shows significant sales, and institutional ownership stands at 66.35%. The stock opened at $14.83, with a market cap of $2.20 billion and a recent earnings report showing a revenue increase of 30.4% year-over-year.</p>

Market Beat

iShares US Medical Devices

Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Rating of "Moderate Buy" by Brokerages